Kathryn Kiehn in Deerfield, Illinois

Medical School: Rush Medical College Of Rush University
Graduation Year: 2005
The Primary Medical Specialty for Kathryn Kiehn is listed as: Rheumatology
Approximate Years of Experience: 19
PAC (PECOS ID)#: 4486842838
NPI #: 1700834348
NPI Created On: 05/05/2006
NPI Last Updated Listed as: 02/19/2019
Primary Taxonomy Code: 207RR0500X
License Number:
36133721
Listed Gender: Female

Forms of insurance accepted by include, but are not limited to:

• Children's Community Health Plan
• Blue Cross Blue Shield
• Medicare

They are listed as accepting new patients.

Languages spoken by staff include: English.

Services and Procedures include:

1. Insertion of needle into vein for collection of blood sample
2. Infusion into a vein for therapy, prevention, or diagnosis up to 1 hour
3. Infusion into a vein for therapy, prevention, or diagnosis
4. Injection beneath the skin or into muscle for therapy, diagnosis, or prevention
5. Injection of drug or substance into a vein for therapy, diagnosis, or prevention
6. Infusion of chemotherapy into a vein up to 1 hour
7. Infusion of chemotherapy into a vein
8. New patient office or other outpatient visit, typically 45 minutes
9. Established patient office or other outpatient visit, typically 15 minutes
10. Established patient office or other outpatient, visit typically 25 minutes
11. Physician telephone patient service, 11-20 minutes of medical discussion
12. Physician telephone patient service, 21-30 minutes of medical discussion
13. Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)
14. Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)
15. Injection, denosumab, 1 mg
16. Injection, methylprednisolone acetate, 40 mg
17. Injection, ferric carboxymaltose, 1 mg
18. Injection, golimumab, 1 mg, for intravenous use
19. Injection, infliximab, excludes biosimilar, 10 mg
20. Injection, romosozumab-aqqg, 1 mg